ProCE Banner Activity

Changing the Course of Outcomes in NSCLC: Immunotherapy Approaches for Early-Stage Disease

Slideset Download

Download this slideset to review key data on the rationale for and use of immune checkpoint inhibition for the treatment of resectable early-stage NSCLC.

Released: September 13, 2021

Share

Faculty

Justin F. Gainor

Justin F. Gainor, MD

Associate Professor
Department of Medicine
Harvard Medical School
Assistant in Medicine
Department of Medicine
Director, Center for Thoracic Cancers
Director of Targeted Immunotherapy
Massachusetts General Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Genentech, a member of the Roche Group

Program Director Disclosure

Program Director

Justin F. Gainor, MD

Associate Professor
Department of Medicine
Harvard Medical School
Assistant in Medicine
Department of Medicine
Director, Center for Thoracic Cancers
Director of Targeted Immunotherapy
Massachusetts General Hospital
Boston, Massachusetts